Status:

UNKNOWN

Study Investigating the Efficacy of Crenolanib With Chemotherapy vs Chemotherapy Alone in R/R FLT3 Mutated AML

Lead Sponsor:

Arog Pharmaceuticals, Inc.

Conditions:

Relapsed/Refractory Acute Myeloid Leukemia With FLT3 Activating Mutations

Eligibility:

All Genders

18-75 years

Phase:

PHASE3

Brief Summary

This is a randomized, multi-center, double-blind, placebo-controlled study designed to evaluate the efficacy of crenolanib administered following salvage chemotherapy, consolidation chemotherapy, post...

Eligibility Criteria

Inclusion

  • Confirmed diagnosis of AML according to World Health Organization (WHO) 2016 classification
  • Presence of FLT3-ITD and/or D835 mutation(s)
  • Subjects must be primary refractory or relapsed to 1st line intensive treatment for AML or refractory or relapsed after second line of treatment for AML
  • Age ≥ 18 years and ≤ 75 years
  • Adequate hepatic function
  • Adequate renal functions
  • ECOG performance status ≤ 3

Exclusion

  • Known clinically active central nervous system(CNS) leukemia
  • Severe liver disease
  • Known, active infection with hepatitis B virus (HBV) or hepatitis C virus (HCV)
  • Prior anti-leukemia therapy within the 14 days prior to randomization. Prior use of quizartinib or gilteritinib must be discontinued 21 days prior to randomization. Prior use of hydroxyurea or other palliative treatment for leukocytosis is allowed.
  • Previous treatment with crenolanib or prior participation in clinical trial involving crenolanib.

Key Trial Info

Start Date :

June 5 2018

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

October 1 2024

Estimated Enrollment :

322 Patients enrolled

Trial Details

Trial ID

NCT03250338

Start Date

June 5 2018

End Date

October 1 2024

Last Update

April 30 2021

Active Locations (62)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 16 (62 locations)

1

City of Hope National Medical Center

Sacramento, California, United States, 95817

2

UC Davis Comprehensive Cancer Center

Sacramento, California, United States, 95817

3

University of Florida

Gainesville, Florida, United States, 32610

4

University of Chicago

Chicago, Illinois, United States, 60637